NCT06836999 (PRIORI-AF) is a NA clinical trial of deep sedation in Atrial Fibrillation, sponsored by The First Affiliated Hospital of Dalian Medical University.

Who is sponsoring NCT06836999?

NCT06836999 is sponsored by The First Affiliated Hospital of Dalian Medical University.

What drugs are being tested in NCT06836999?

Interventions in NCT06836999: deep sedation, Conscious sedation.

What condition does NCT06836999 study?

NCT06836999 studies Atrial Fibrillation, Atrial Fibrillation, Paroxysmal or Persistent, Deep Sedations, Conscious Sedation.

Is NCT06836999 still recruiting?

NCT06836999 is currently not yet recruiting. Last updated 4 March 2025.

Last reviewed 2025-03-04 · How we verify

NCT06836999: PRIORI-AF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deep Sedation in Catheter Ablation of Atrial Fibrillation

Not yet recruiting NA Last updated 4 March 2025

What this trial tests

NA trial testing deep sedation in Atrial Fibrillation in 1,334 participants. Not yet recruiting.

Timeline

3 March 2025

Primary endpoint
31 July 2027

31 December 2027

Quick facts

Lead sponsor	The First Affiliated Hospital of Dalian Medical University
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1,334
Start date	3 March 2025
Primary completion	31 July 2027
Estimated completion	31 December 2027
Sites	16 locations across China

Drugs / interventions tested

deep sedation
Conscious sedation — full drug profile →

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →
Atrial Fibrillation, Paroxysmal or Persistent — all drugs for Atrial Fibrillation, Paroxysmal or Persistent →
Deep Sedations — all drugs for Deep Sedations →
Conscious Sedation — all drugs for Conscious Sedation →

Sponsor

The First Affiliated Hospital of Dalian Medical University

Who can join

Adults 18 to 75, any sex, with Atrial Fibrillation or Atrial Fibrillation, Paroxysmal or Persistent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current practice of anesthesia for atrial fibrillation catheter ablation （CA） procedure is inconsistent, including general anesthesia, deep sedation, and conscious sedation.Due to the nature of deep sedation, it has been continuously gaining its position as one of the crucial components in standard practices of atrial fibrillation ablation during the last decade. Currently, a considerable number of procedures have been done using conscious sedation. Previous studies explored the benefits obtained from the employment of deep sedation in AF ablation procedures, mainly focused on pain reduction and intra-procedural safety. However, the benefits on long-term rhythmic outcomes, peri-procedural safety as well as benefits on procedural parameters and peri-procedural experiences from patients/ablators/lab staff have yet not to be thoroughly studied. We plan to conduct a prospective, multicenter, randomized, controlled trial to evaluate the benefits of deep sedation in catheter ablation of paroxysmal and persistent AF in multiple prospective, i.e., quantified intraprocedural patients / physicians / lab staffs / mapper clinical specialist experiences, and the procedure safety.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Other The First Affiliated Hospital of Dalian Medical University trials

Trials by the same sponsor.

NCT07397390 — an Observational Study Evaluting the Effectiveness and Safety of DKutting LL Noval Scoring Balloon Angioplasty for Vesse · enrolling by invitation
NCT06356701 — Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC · Phase 1 · unknown
NCT06250842 — Benzodiazepine Impact on Cognitive Function: fNIRs and PET/MRI Study · recruiting
NCT06056973 — Jinghua Weikang Capsule in the Treatment of Reflux Esophagitis · Phase 4 · unknown
NCT05418465 — Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06836999 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Dalian Medical University
Last refreshed: 4 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06836999.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing